Skip to main content

Genomic Breast Cancer Epidemiology - Linda Sofie Lindström

The Lindström research group’s main scientific interest is in the search of understanding the specific patient and tumor characteristics required throughout tumor progression to enable the cancer tumor to gain early or late metastatic capacity, in the end responsible for virtually all cancer-related death.

Our research is focused around breast cancer being the most common cancer and cause of death in women in the Western world. Breast cancer is widely recognized as a diverse disease both in the sense of primary tumor metastatic capacity and time to metastatic spread of disease. It has a long natural history, occasionally spanning more than 20 years between primary tumor diagnosis and metastatic disease. Endocrine (hormonal) therapy is a major cornerstone in the management of breast cancer, today selected based on tumor hormonal receptor positivity, improving patient survival considerably. However, despite achievements in the use of different adjuvant therapies, one out of five women with early-stage breast cancer will later develop distant metastatic disease. Hence, there is a need for a refined way of identifying patients at high risk for metastatic disease and thus fatal outcome for individualized therapeutic interventions.

Main research questions:

  • Does intra-tumor heterogeneity influence patient survival and response to therapy?
  • Long-term risk: Which factors are important for the long-term risk for fatal breast cancer disease? Identify patients at high and very low risk.
  • Breast cancer in situ: Who is at high and low risk to develop invasive breast cancer?
  • Why do young women with breast cancer have a high risk of fatal breast cancer?
  • Is breast cancer survival inherited?

Team members

Group leader

Linda Sofie Lindström

Telefon: 08-524 881 17
Enhet: Institutionen för biovetenskaper och näringslära (BioNut), H2


Athanasia Christakou

Enhet: Lindström


Huma Dar


Selected publications

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
Lindström L, Yau C, Czene K, Thompson C, Hoadley K, Van't Veer L, et al
J. Natl. Cancer Inst. 2018 Jul;110(7):726-733

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Esserman L, Yau C, Thompson C, van 't Veer L, Borowsky A, Hoadley K, et al
JAMA Oncol 2017 Nov;3(11):1503-1510